Because my colleagues seem to be catching up with the translation, I'll have a go at this.
I'm assuming that you're talking about off-label use of prescription drugs.
You are essentially talking about off-label use of drugs.
Several weeks ago, at a Health Canada meeting, I was surprised to discover that, for certain drugs in certain populations, such as the pediatric population, off-label use is more extensive than on-label use. The figures are really quite astonishing. You are right to say that this is not consistent with the regulations, but the fact is that medicine is constantly evolving, and off-label use of drugs can have some fairly significant beneficial effects.
I believe this brings us back to the previous question, which has to do with communication. There has to be a means of communicating quickly with the people writing prescriptions, the people using them and Health Canada, so that we can bring all those results together and arrive at a system that offers maximum benefits to patients.
That is a little outside of parameters of your question, but it is a very difficult issue.